Valbiotis Announces Its Roadmap for 2023: a Pivotal Year in the Execution of Its Clinical, Industrial and Commercial Strategy

A decisive year in clinical terms with results expected in the first half of 2023 from the international Phase II/III REVERSE-IT study on TOTUM•63, a plant-based active substance that has already

Related Keywords

Quebec ,Canada ,France ,Riom ,Auvergne ,French , ,European Regional Development Fund ,Health Science ,Research Development ,Young Innovative Company ,Valbioti Business Development Department ,Public Affairs ,European Union ,Innovative Company ,Valbioti Business Development ,Valbiotis Board ,Quebec City ,Valbiotis Universal Registration Document ,French Financial Markets Regulator ,Valbiotis ,Nnounces ,Roadmap ,023 ,Pivotal ,Ear ,Execution ,Linical ,Industrial ,Commercial ,Strategy ,